Evidence map›Paper›PMID 31172843›Full record

ArticleDrug delivery2019

New micelle myricetin formulation for ocular delivery: improved stability, solubility, and ocular anti-inflammatory treatment.

Fengyuan Sun, Zhou Zheng, Jie Lan, Xuefei Li, Mengshuang Li, Kaichao Song, Xianggen Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 84 citations in OpenAlex.

  1. Mucoadhesive micelles for ophthalmic drug delivery.Journal of biomaterials applications · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Recent development of polymer nanomicelles in the treatment of eye diseases.Frontiers in bioengineering and biotechnology · 2023
    Review
  14. Review
  15. Review
  16. SoluplusDrug delivery and translational research · 2022
    Article
  17. Review
  18. Review
  19. Article
  20. Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Fengyuan Suna Department of Pharmacy, College of Chemical Engineering , Qingdao University of Science and Technology , Qingdao , China.
Zhou Zhengb Key Laboratory of Marine Bioactive Substances , First Institute of Oceanography, State Oceanic Administration , Qingdao , China.
Jie Lanc Qingdao Eye Hospital, Shandong Eye Institute , Shandong Academy of Medical Sciences , Qingdao , China.
Xuefei Lia Department of Pharmacy, College of Chemical Engineering , Qingdao University of Science and Technology , Qingdao , China.
Mengshuang Lia Department of Pharmacy, College of Chemical Engineering , Qingdao University of Science and Technology , Qingdao , China.
Kaichao Songa Department of Pharmacy, College of Chemical Engineering , Qingdao University of Science and Technology , Qingdao , China.
Xianggen Wua Department of Pharmacy, College of Chemical Engineering , Qingdao University of Science and Technology , Qingdao , China.
Qingdao University of Science and Technology · CNFirst Institute of Oceanography · CNQingdao Women and Children's Hospital · CNShandong First Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myricetin (Myr) is a naturally occurring flavonoid exhibiting diverse biological and pharmacological properties, but its characteristics such as water insolubility, poor aqueous stability, and poor bioavailability limit its clinical application, including in ophthalmology. To increase its clinical application in ophthalmology, Myr was designed to be encapsulated in a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (PVCL-PVA-PEG) polymeric micelles to increases its aqueous solubility, stability, and corneal permeability to promote its efficacy in eye disease treatments. Thus, the Myr micelle ophthalmic solution was prepared and characterized encapsulation efficiency (EE), micelle size, and zeta potential. The chemical stability of Myr and the short-term storage stability of the Myr micelle ophthalmic solution were evaluated, followed by

Indexed as

Administration, OphthalmicAnimalsAnti-Inflammatory AgentsChemistry, PharmaceuticalCorneaDrug CarriersDrug Delivery SystemsFlavonoidsMicellesOphthalmic SolutionsPermeabilityPolyethylene GlycolsPolymersPolyvinylsRabbitsSolubilityAnti-Inflammatory AgentsDrug CarriersFlavonoidsMicellesmyricetinOphthalmic SolutionsPolyethylene GlycolsPolymerspolyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymerPolyvinylsmicelleMyricetinocular drug deliverypolyvinyl caprolactam–polyvinyl acetate–polyethylene glycol graft copolymerstability

Identifiers

PMID31172843
PMCPMC6567238
OpenAlexW2948295497

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.